Member Exclusive

Newly Released Peer-Reviewed Publication Further Validates RepliCel’s Use of Dermal Sheath Cup Cells to Treat Pattern Baldness

RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today the publication of a paper out of the University of Calgary in conjunction with co-authors from Kyoto University and the University of North Carolina, which further validates the company's ongoing clinical research using dermal sheath cup (DSC) cells to reverse the effects of pattern baldness.

Go to the profile of Lee Buckler
Dec 22, 2014
0
0

Please sign in or register for FREE

Register to RegMedNet

RegMedNet is a free content and networking hub promoting global connection, knowledge-sharing and collaboration between all members of the regenerative medicine field.

Register

No comments yet.